Volume | 2,782 |
|
|||||
News | - | ||||||
Day High | 1.10 | Low High |
|||||
Day Low | 1.00 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Protagenic Therapeutics Inc | PTIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1.10 | 1.00 | 1.10 | 1.05 | 1.08 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
43 | 2,782 | US$ 1.04 | US$ 2,897 | - | 0.6797 - 2.22 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
15:00:00 | 100 | US$ 1.05 | USD |
Protagenic Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.66M | 4.44M | - | 0 | -5M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Protagenic Therapeutics News
Date | Time | Source | News Article |
---|---|---|---|
2/14/2024 | 13:29 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
12/15/2023 | 14:50 | Edgar (US Regulatory) | Form 8-K - Current report |
11/29/2023 | 16:18 | Edgar (US Regulatory) | Form 8-K - Current report |
11/14/2023 | 15:02 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
11/02/2023 | 15:29 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
10/13/2023 | 11:48 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
8/14/2023 | 14:29 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTIX Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.41 | 1.42 | 1.00 | 1.17 | 8,793 | -0.36 | -25.53% |
1 Month | 1.32 | 1.87 | 1.00 | 1.63 | 24,142 | -0.27 | -20.45% |
3 Months | 1.16 | 1.87 | 1.00 | 1.57 | 15,753 | -0.11 | -9.48% |
6 Months | 0.8688 | 1.87 | 0.7336 | 1.34 | 11,927 | 0.1812 | 20.86% |
1 Year | 1.96 | 2.22 | 0.6797 | 1.31 | 10,311 | -0.91 | -46.43% |
3 Years | 9.72 | 16.76 | 0.6797 | 9.25 | 164,703 | -8.67 | -89.20% |
5 Years | 11.00 | 19.56 | 0.6797 | 11.25 | 428,812 | -9.95 | -90.45% |
Protagenic Therapeutics Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |